Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2026-03-18 Director's Dealing
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
Director's Dealing
2026-03-18 English
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
Director's Dealing
2026-03-18 English
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
Director's Dealing
2026-03-18 English
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
Director's Dealing
2026-03-18 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Kazia Therapeutics Limited. It reports the issuance of a press release about preliminary clinical responses in a study. The document is short (1850 characters) and primarily serves to announce the press release, which is attached as Exhibit 99.1. There is no substantive financial data or detailed report content within this filing itself. According to the rules, such a document that announces or attaches a press release without containing the full report or financial data should be classified as a Regulatory Filing (RNS).
2026-01-27 English
424B3 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a press release providing a clinical update on an ongoing Phase 1b study. The document is a regulatory filing that supplements previously filed registration statements and prospectuses. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is not an earnings release, management report, or investor presentation. The document primarily serves as a current report to update investors and the SEC on clinical progress and related corporate information. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2026-01-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.